



27W

PATENT  
ATTORNEY DOCKET NO. 50164/033002

Certificate of Mailing: Date of Deposit: August 1, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan M. Cannon  
Printed name of person mailing correspondence

*Susan M. Cannon*  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Edward Roydon Jost-Price et al. Confirmation No.: 6397  
Serial No.: 10/777,518 Art Unit: 1617  
Filed: February 12, 2004 Examiner: Jennifer M. Kim  
Customer No.: 21559  
Title: COMBINATION THERAPY FOR THE TREATMENT OF  
IMMUNOINFLAMMATORY DISORDERS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. Copies of Search Reports from counterpart International and European applications are also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is

material to patentability.


This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: \_\_\_\_\_

7/27/06



Michael J. Belliveau, Ph.D.

Reg. No. 52,608

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

Sheet 1 of 8

<b>SUBSTITUTE FORM PTO-1449</b> (MODIFIED)  <b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	<b>Attorney Docket No.</b>	50164/033002
	<b>Serial No.</b>	10/777,518
	<b>Applicant</b>	Jost-Price et al.
	<b>Filing Date</b>	February 12, 2004
	<b>Group</b>	1617
	<b>IDS Filed</b>	August 1, 2006
	<b>Customer No.</b>	21559

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	4,444,780	Apr. 24, 1984	Capetola et al.			
	6,096,737	Aug. 1, 2000	Loder			
	6,140,337	Oct. 31, 2000	Binder et al.			
	6,258,816	Jul. 10, 2001	Singh et al.			
	6,423,721	Jul. 23, 2002	Harris et al.			
	6,472,401	Oct. 29, 2002	Kreutner			
	6,492,400	Dec. 10, 2002	Ko et al.			
	6,599,914	July 29, 2003	Schleimer et al.			
	6,777,441	Aug. 17, 2004	Wang et al.			
	7,034,059	April 25, 2006	Currie et al.			
	2002/0006961	Jan. 17, 2002	Katz et al.			
	2002/0061281	May 23, 2002	Osbakken et al.			
	2005/0192261	Sept. 1, 2005	Jost-Price et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	GB 1,101,104	Jan. 31, 1968	Great Britain			
	WO 92/08474	May 29, 1992	WIPO			
	WO 97/01337	Jan. 16, 1997	WIPO			
	WO 97/046243	Dec. 11, 1997	WIPO			
	WO 98/11908	Mar. 26, 1998	WIPO			

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50164/033002
	Serial No.	10/777,518
	Applicant	Jost-Price et al.
	Filing Date	February 12, 2004
	Group	1617
	IDS Filed	August 1, 2006
	Customer No.	21559

	WO 98/52594	Nov. 26, 1998	WIPO			
	WO 01/85206	Nov. 15, 2001	WIPO			
	WO 02/051814	Jul. 4, 2002	WIPO			
	WO 02/080916	Oct. 17, 2002	WIPO			
	WO 03/030823	Apr. 17, 2003	WIPO			
	WO 03/037349	May 8, 2003	WIPO			
	WO 03/039548	May 15, 2003	WIPO			
	WO 03/042174	May 22, 2003	WIPO			
	WO 03/048152	Jun. 12, 2003	WIPO			
	WO 2004/030618	Apr. 15, 2004	WIPO			
	WO 2005/030132	Apr. 7, 2005	WIPO			

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	[No Authors Listed], "Chronisch Entzündliche Darmerkrankungen. Senken Antihistaminika den Steroidbedarf?," (Chronic Inflammatory Bowel Diseases. Do Antihistaminics Reduce the Need for Steroids?) <i>MMW Fortschr. Med.</i> 142:59 (2000). [Article in German]
	Aizenberg et al., "Cyproheptadine Treatment of Sexual Dysfunction Induced by Serotonin Reuptake Inhibitors," <i>Clin. Neuropharmacol.</i> 18:320-324 (1995).
	Aletaha and Smolen, "Advances in Anti-Inflammatory Therapy," <i>Acta Medica Austriaca</i> 29:1-6 (2002).
	Alvarez et al., "Effects of Antidepressants on Histamine H <sub>2</sub> Receptors in Rat Isolated Uterus," <i>J. Pharmacol.</i> 17:351-354 (1986).
	Arnott and Nutt, "Successful Treatment of Fluvoxamine-Induced Anorgasmia by Cyproheptadine," <i>Br. J. Psychiatry</i> 164:838-839 (1994).
	Banfield et al., "No Drug Interaction Between Fluoxetine and Desloratadine, a New Nonsedating Once-daily Antihistamine," <i>J. Aller. Clin. Immunol.</i> 107:S161 (2001). [Abstract 529]
	Belsey et al., "Tricyclic Antidepressants and 2 <sup>nd</sup> Generation Antihistamines Inhibit Volume-Sensitive Anion Channels in HeLa Cells," <i>Br. J. Pharm.</i> 135:Suppl 1P (2002). [Abstract 1P]

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50164/033002
	Serial No.	10/777,518
	Applicant	Jost-Price et al.
	Filing Date	February 12, 2004
	Group	1617
	IDS Filed	August 1, 2006
	Customer No.	21559

	Bendele et al., "Cutaneous Mast Cell Degranulation in Rats Receiving Injections of Recombinant Human Interleukin-1 Receptor Antagonist (rhIL-1ra) and/or Its Vehicle: Possible Clinical Implications," <i>J. Lab. Clin. Med.</i> 125:493-500 (1995).
	Berger et al., "Double-Blind Trials of Azelastine Nasal Spray Monotherapy Versus Combination Therapy with Loratadine Tablets and Beclomethasone Nasal Spray in Patients with Seasonal Allergic Rhinitis," <i>Ann. Allergy Asthma Immunol.</i> 82:535-541 (1999).
	Bernstein et al., "Inhibition of Histamine-Induced Pruritus by Topical Tricyclic Antidepressants," <i>J. Am. Acad. Dermatol.</i> 5:582-585 (1981).
	Biedermann, "Tierexperimenteller Beitrag Zur Therapie des Anaphylaktischen Schocks. Die Kombination von Antihistaminica und Corticosteroiden Beim Meerschweinchen [Experimental Contribution to the Therapy of the Anaphylactic Shock. The Combination of Antihistaminics and Corticosteroids in Guinea Pigs]," <i>Z. Gesamte Exp. Med.</i> 148:194-203 (1968). [Article in German, English Abstract]
	Bierman, "Review Article. Urticaria: The Final Common Pathway," <i>Allergol. Int.</i> 45:171-176 (1996).
	Binazzi and Giovane, "Impiego di Psicofarmaci in Dermatologia," <i>Ann. It. Derm. Clin. Sper.</i> 43:63-69 (1989). [Article in Italian, English Abstract]
	Breyer-Pfaff et al., "Biphasic Kinetics of Quaternary Ammonium Glucuronide Formation from Amitriptyline and Diphenhydramine in Human Liver Microsomes," <i>Drug Metab. Dispos.</i> 25:340-345 (1997).
	Brooks et al., "Effect of Systemic Corticoid and Antihistamine Alone or in Combination on Elements of the Response to a Two Dose Nasal Allergen Challenge," <i>Am. J. Rhinol.</i> 11:117-122 (1997).
	Brubaker, "Fluoxetine-induced Sexual Dysfunction Reversed by Loratadine," <i>J. Clin. Psychiatry</i> 63:534 (2002).
	Bruno et al., "Original Article. Serum Tryptase in Allergic Rhinitis: Effect of Cetirizine and Fluticasone Propionate Treatment," <i>Clin. Ter.</i> 152:299-303 (2001).
	Burrish et al., "Case Report. Sulindac-Induced Anaphylaxis," <i>Ann. Emerg. Med.</i> 10:154-155 (1981).
	Chapler et al., "The Effects of an Antihistamine and/or a Glucocorticoid on the Prolactin Response to Surgical Procedures," <i>Am. J. Obstet. Gynecol.</i> 132:367-372 (1978).
	Chard and Crisp, "Astemizole, an H <sub>1</sub> Antagonist, Has No Additional Therapeutic Effect in Rheumatoid Arthritis," <i>J. Rheumatol.</i> 18:203-204 (1991).
	Chunharas et al., "Therapeutic Efficacy and Safety of Loratadine Syrup in Childhood Atopic Dermatitis Treated with Mometasone Furoate 0.1 Per Cent Cream," <i>J. Med. Assoc. Thai.</i> 85:482-487 (2002).
	Cohen, "Fluoxetine-Induced Yawning and Anorgasmia Reversed by Cyproheptadine Treatment," <i>J. Clin. Psychiatry</i> 53:174 (1992).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50164/033002
	Serial No.	10/777,518
	Applicant	Jost-Price et al.
	Filing Date	February 12, 2004
	Group	1617
	IDS Filed	August 1, 2006
	Customer No.	21559

	de la Gandara et al., "Effects of Antidepressants of Alcohol-Induced Gastric Mucosal Injury in Rats," <i>Meth. and Find. Exp. Clin. Pharmacol.</i> 11:635-639 (1989).
	Di Gioacchino et al., "Steroid and Antihistamines Modulate RANTES Release in Cultured Peripheral Blood Mononuclear Cells of Atopic Patients," <i>Int. J. Immunopathol. Pharmacol.</i> 15:27-34 (2002).
	Diehn et al., "Short Report. Pruritus in Polycythaemia Vera: Prevalence, Laboratory Correlates and Management," <i>Brit. J. Haematol.</i> 115:619-621 (2001).
	Doggrell, "Triamcinolone: New and Old Indications," <i>Expert Opin. Pharmacother.</i> 2:1177-1186 (2001).
	Edwards, et al., "Changes in Numbers of Epidermal Cell Adhesion Molecules Caused by Oral Cyclosporin in Psoriasis," <i>J. Clin. Pathol.</i> 46:713-717 (1993).
	Feder, "Reversal of Antidepressant Activity of Fluoxetine by Cyproheptadine in Three Patients," <i>J. Clin. Psychiatry</i> 52:163-164 (1991).
	Friedmann et al., "Treatment of Sleep Disturbance in Alcohol Recovery: A National Survey of Addiction Medicine Physicians," <i>J. Addictive Diseases</i> 22:91-103 (2003).
	Geist et al., "Effect of the Lipooxygenase Inhibitor N-Hydroxy-N-(6-methoxy-3,4-dihydro-2-naphthylmethyl)urea on Bronchoconstriction and Lung Vascular Permeability in Anaphylactic Guinea Pigs," <i>Arzneim. Forsch. Drug Res.</i> 45:155-158 (1995).
	Goldbloom and Kennedy, "Adverse Interaction of Fluoxetine and Cyproheptadine in Two Patients with Bulimia Nervosa," <i>J. Clin. Psychiatry</i> 52:261-262 (1991).
	Goldsobel et al., "Efficacy of Doxepin in the Treatment of Chronic Idiopathic Urticaria," <i>J. Aller. Clin. Immunol.</i> 78:867-873 (1986).
	Grattan et al., "Blood Basophil Numbers in Chronic Ordinary Urticaria and Healthy Controls: Diurnal Variation, Influence of Loratadine and Prednisolone and Relationship to Disease Activity," <i>Clin. and Exp. Allergy</i> 33:337-341 (2003).
	Grossman and Brahn, "Rheumatoid Arthritis: Current Clinical and Research Directions," <i>J. Women's Health</i> 6:627-638 (1997).
	Gupta and Gupta, "Chronic Idiopathic Urticaria Associated with Panic Disorder: A Syndrome Responsive to Selective Serotonin Reuptake Inhibitor Antidepressants?," <i>Cutis</i> 56:53-54 (1995).
	Gupta and Gupta, "Review Article. The Use of Antidepressant Drugs in Dermatology," <i>J. Eur. Acad. Dermatol. Venereol.</i> 15:512-518 (2001).
	Gupta et al., "Depression Modulates Pruritus Perception: A Study of Pruritus in Psoriasis, Atopic Dermatitis, and Chronic Idiopathic Urticaria," <i>Psychosom. Med.</i> 56:36-40 (1994).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50164/033002
	Serial No.	10/777,518
	Applicant	Jost-Price et al.
	Filing Date	February 12, 2004
	Group	1617
	IDS Filed	August 1, 2006
	Customer No.	21559

	Hall et al., "Effect of Cortisol and Cyproheptadine on Anaphylactoid and Arthritic Responses of the Rat to Dextran," <i>Arch. Int. Pharmacodyn. Ther.</i> 201:314-322 (1973).
	Harto et al., "Doxepin in the Treatment of Chronic Urticaria," <i>Dermatologica</i> 170:90-93 (1985).
	Kelley and Porter, "The Role of Muscarinic Cholinergic Receptors in the Discriminative Stimulus Properties of Clozapine in Rats," <i>Pharmacol. Biochem. Behav.</i> 57:707-719 (1997).
	Kleine-Tebbe et al., "Modulation of IgE-mediated Histamine Release from Human Leukocytes by a New Class of Histamine H <sub>2</sub> -Agonists," <i>Inflammation Research (Agents Actions)</i> 35:185-191 (1992).
	Kühnau, "Ertolan, Eine Neue Kortikoid-Antihistamin-Chemotherapeutikum-Kombination in Salbenform [Ertolan, A New Corticoid-Antihistamine Therapeutic Combination in Ointment Form]," <i>Med. Klin.</i> 62:1023-1025 (1967). [Article in German]
	Kuran et al., "The Efficacy of Combined Medical Treatment (Antihistaminics, Steroids, and Macrolide Antibiotics) in Patients with Nasal Polyposis: Preliminary Results," <i>Kulak Burun Bogaz Ihtis. Derg.</i> 9:352-357 (2002). [English Abstract Only]
	Leung and Bieber, "Seminar. Atopic Dermatitis," <i>The Lancet</i> 361:151-160 (2003).
	Lippmann et al., "Featured CME Topic: Primary Care Issues. Insomnia: Therapeutic Approach," <i>South. Med. J.</i> 94:866-873 (2001).
	Louis et al., "LY 186655, A Phosphodiesterase Inhibitor, Inhibits Histamine Release from Human Basophils, Lung and Skin Fragments," <i>Int. J. Immunopharmacol.</i> 14:191-194 (1992).
	Maillefert et al., "Ranitidine Induced Polyarthropathy," <i>Therapie</i> 49:152-153 (1994).
	Malone et al., "In Vivo Effects of Nonsteroidal Antiinflammatory Drugs on Rat Skin and Synovial Mast Cell-Induced Vasopermeability," <i>Arthr. Rheum.</i> 34:164-170 (1991).
	Martin-Jimenez et al., "Results of Two Controlled Studies on Antiemetic Combination Against Vomiting Induced by 5-Fluorouracil," <i>Tumori</i> 73:499-504 (1987).
	Matuška et al., "Rush Immunotherapy with the Standardised Grass-Pollen Extract in Children with Mild Allergic Asthma. A Comparison of Two Premedication Regimens," <i>Scripta Medica (BRNO)</i> 74:367-378 (2001).
	Miller et al., "Original Article. Clinical and Biochemical Effects of Catecholamine Depletion on Antidepressant-Induced Remission of Depression," <i>Arch. Gen. Psychiatry</i> 53:117-128 (1996).
	Murphy et al., "Expedited Publication. Suppression of Carbamazepine-Induced Rash with Prednisone," <i>Neurol.</i> 41:144-145 (1991).
	Negro-Alvarez et al., "Pharmacologic Therapy for Urticaria," <i>Allergol. Immunopathol.</i> 25:36-51 (1997).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/033002
		Serial No.	10/777,518
		Applicant	Jost-Price et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	February 12, 2004
		Group	1617
		IDS Filed	August 1, 2006
		Customer No.	21559
(37 C.F.R. § 1.98(b))			

	Nielsen and Hammer, "Possible Role of Histamine in Pathogenesis of Autoimmune Diseases: Implications for Immunotherapy with Histamine-2 Receptor Antagonists," <i>Med. Hypoth.</i> 39:349-355 (1992).
	Nielsen, "Histamine and Histamine Type-2 Receptor Antagonists in Psoriasis," <i>Dan. Med. Bull.</i> 38:478-480 (1991).
	Nishida et al., "Suppression by Adenine Compounds of Histamine-induced Contraction in Isolated Guinea Pig Tracheal Rings," <i>Pharmacol.</i> 24:283-286 (1982).
	Odashima et al., "Anti-Inflammatory Effects of Selective A2A Adenosine Receptor Agonism in Experimental Inflammatory Bowel Disease (IBD)," [Abstract 1448, A-280].
	Orlov and Rabinovich, "A New Approach to Overcoming Drug Resistance of Some Malaria Parasites," <i>Med. Parazitol.</i> 5:18-21 (1990). [Article in Russian, English Abstract]
	Ormerod, "Practical Therapeutics. Urticaria. Recognition, Causes and Treatment," <i>Drugs</i> 48:717-730 (1994).
	Permin et al., "Possible Role of Histamine in Rheumatoid Arthritis. Treatment with Cimetidine and Mepyramine," <i>Allergy</i> 36:435-436 (1981).
	Pestelli et al., "Cetirizine Reduces the Number of Tryptase-Positive Mast Cells in Psoriatic Patients: A Double-blind Controlled Study," <i>Int. J. Tissue React.</i> 23:97-103 (2001).
	Petersen et al., "Studies on Mast Cells and Histamine Release in Psoriasis: The Effect of Ranitidine," <i>Acta Derm. Venereol. (Stockh)</i> 78:190-193 (1998).
	Portmann et al., "Therapeutic Note. Acceptability of Topical Administration of a Combination of Corticoid (Beclomethasone) and Antihistamine (Azelastine) in the Treatment of Allergic Rhinitis," <i>Rev. Laryngol. Otol. Rhinol.</i> 121:273-279 (2000). [Article in French, English Abstract]
	Prenner, "The Evolution of Pharmacotherapy for Rhinitis and Urticaria," <i>Aller. and Asth. Proc.</i> 22:277-280 (2001).
	Pullerits et al., "Comparison of a Nasal Glucocorticoid, Antileukotriene, and a Combination of Antileukotriene and Antihistamine in the Treatment of Seasonal Allergic Rhinitis," <i>J. Allergy Clin. Immunol.</i> 109:949-955 (2002).
	Purello-D'Ambrosio et al., "A Controlled Study on the Effectiveness of Loratadine in Combination with Flunisolide in the Treatment of Nonallergic Rhinitis with Eosinophilia (NARES)," <i>Clin. Exp. Allergy</i> 29:1143-1147 (1999).
	Raithel et al., "Application of the H <sub>1</sub> Receptor Antagonist Loratadine Reduces Steroid Consumption in Active Crohn's Disease (CD)," [Abstract 1449, A-280].
	Rao et al. "Duration of the Suppressive Effect of Tricyclic Antidepressants on Histamine-Induced Wheal-and-Flare Reactions in Human Skin," <i>J. Allergy Clin. Immunol.</i> 82:752-757 (1988).
	Ratner et al., "Original Research. A Comparison of the Efficacy of Fluticasone Propionate Aqueous Nasal Spray and Loratadine, Alone and in Combination, for the Treatment of Seasonal Allergic Rhinitis," <i>J. Family Pract.</i> 47:118-125 (1998).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50164/033002
	Serial No.	10/777,518
	Applicant	Jost-Price et al.
	Filing Date	February 12, 2004
	Group	1617
	IDS Filed	August 1, 2006
	Customer No.	21559

	Reicin et al., "Original Investigation. Montelukast, a Leukotriene Receptor Antagonist, in Combination with Loratadine, a Histamine Receptor Antagonist, in the Treatment of Chronic Asthma," <i>Arch. Intern. Med.</i> 160:2481-2499 (2000).
	Richelson, "Laboratory Study. Tricyclic Antidepressants and Histamine H <sub>1</sub> Receptors," <i>Mayo Clin. Proc.</i> 54:669-674 (1979).
	Rothe and Grant-Kels, "Continuing Medical Evaluation. Atopic Dermatitis: An Update," <i>J. Am. Aca. Dermatol.</i> 35:1-13 (1996).
	Sabroe et al., "The Effects of Topical Doxepin on Responses to Histamine, Substance P and Prostaglandin E <sub>2</sub> in Human Skin," <i>Br. J. Dermatol.</i> 137:386-390 (1997).
	Sannicandro et al., "Selective Serotonin Reuptake Inhibitor-Induced Rash: Case Report and Review of the Literature," <i>Pharmacother.</i> 22:516-518 (2002).
	Sarangapani and Reddy, "Research Paper. Pharmacological Screening of Isatin-[N-(2-alkylbenzoxazol-5-carbonyl)] Hydrazones," <i>Indian J. Pharm. Sci.</i> 59:105-109 (1997).
	Scremin and Caprioglio, "Treatment of Asthma with an Extempore Combination of a Bronchodilator, Salbutamol, and a New Antihistamine Drug, Oxatomide," <i>Int. J. Clin. Pharmacol. Res.</i> 6:105-111 (1986).
	Song et al., "Behavioral and Immunological Effects of the Antihistamine Terfenadine in Olfactory Bulbectomized Rats," <i>Eur. Neuropsychopharm.</i> 6:157-162 (1996).
	Tarng et al., "Teaching Point. Peritonitis in CAPD Patients – Do Not Always Use Antibiotics!," <i>Nephrol. Dial. Transplant</i> 16:856-858 (2001).
	Tedeschi et al., "Leading Article. Chronic Urticaria: A Role for Newer Immunomodulatory Drugs?," <i>Am. J. Clin. Dermatol.</i> 4:297-305 (2003).
	Tsai and Yellin, "Differences in the Interaction of Histamine H <sub>2</sub> Receptor Antagonists and Tricyclic Antidepressants with Adenylate Cyclase from Guinea Pig Gastric Mucosa," <i>Biochem. Pharmacol.</i> 33:3621-3625 (1984).
	Twycross et al., "Review. Itch: Scratching More than the Surface," <i>Q. J. Med.</i> 96:7-26 (2003).
	Weber et al., "New Systemic Therapies of Psoriasis," <i>Der Hautarzt.</i> 36:20-24 (1985). [Article in German. English Abstract]
	Wilson et al., "Antiasthmatic Effects of Mediator Blockade Versus Topical Corticosteroids in Allergic Rhinitis and Asthma," <i>Am. J. Respir. Crit. Care Med.</i> 162:1297-1301 (2000).
	Wilson et al., "Effects of Monotherapy with Intra-Nasal Corticosteroid or Combined Oral Histamine and Leukotriene Receptor Antagonists in Seasonal Allergic Rhinitis," <i>Clin. Exp. Allergy</i> 31:61-68 (2001).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/033002
		Serial No.	10/777,518
		Applicant	Jost-Price et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	February 12, 2004
		Group	1617
		IDS Filed	August 1, 2006
		Customer No.	21559
(37 C.F.R. § 1.98(b))			

	Yamaura et al., "Full Paper. The Histamine H <sub>2</sub> -Receptor Antagonist, Cimetidine, Inhibits the Articular Osteopenia in Rats With Adjuvant-Induced Arthritis by Suppressing the Osteoclast Differentiation Induced by Histamine," <i>J. Pharmacol. Sci.</i> 92:43-49 (2003).
	Yap and Camm, "The Current Cardiac Safety Situation with Antihistamines," <i>Clin. Exper. Aller.</i> 29:15-24 (1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	